WHITE PAPER
Securing Sustainable Reimbursement for Cell and Gene Therapies
May 22, 2023

Cell and gene therapies (CGTs) hold great promise in treating a variety of orphan diseases that previously had no viable cure. With more than 6,000 such diseases afflicting over 350 million patients worldwide, CGTs collectively have the ability to make a substantial impact on society.

However, clinical trial designs, regulation and reimbursement have faced major hurdles that limit patient access to CGTs advancement. This white paper dissects each of these hurdles, challenges within the CGTs reimbursement landscape, and proposed potential solutions to enable patient access to CGTs treatment products with possibly less burden.

For more information, contact us.

Authors

  • Dr. Wang Xueying, Sherry, Principal Director and Head, Regulatory Commercial Services, SEA & APAC RHQ, IQVIA
  • Geraldine John, Manager, Consulting Services, SEA & APAC RHQ, IQVIA
  • Dr. Akansha Gupta, Analyst, Consulting Services, Pricing & Market Access CoE, IQVIA
Contact Us